DataSheet_1_Minimal residual disease status improved the response evaluation in patients with Waldenström’s macroglobulinemia.docx

IntroductionMinimal residual disease (MRD) has been recognized as an important prognostic factor of survival in patients with hematological malignancies. However, the prognostic value of MRD in Waldenström macroglobulinemia (WM) remains unexplored.MethodsWe analyzed 108 newly diagnosed WM patients receiving systematic therapy and assessed for MRD by multiparameter flow cytometry (MFC) using bone marrow samples.ResultsOf the total patients, 34 (31.5%) achieved undetectable MRD (uMRD). A hemoglobin level of >115 g/L (P=0.03), a serum albumin level of >35 g/L (P=0.01), a β2-MG level of ≤3 mg/L (P=0.03), and a low-risk International Prognostic Scoring System for WM (IPSSWM) stage (P

引言最小残留病（MRD）已被确认为血液恶性肿瘤患者生存的重要预后因素。然而，MRD在华氏巨球蛋白血症（WM）中的预后价值尚待研究。方法我们对接受系统性治疗的108例新诊断的WM患者进行了分析，并通过骨髓样本的多参数流式细胞术（MFC）评估MRD。结果在所有患者中，有34例（31.5%）实现了不可检测的MRD（uMRD）。血红蛋白水平大于115 g/L（P=0.03）、血清白蛋白水平大于35 g/L（P=0.01）、β2-MG水平≤3 mg/L（P=0.03）以及低风险国际预后评分系统WM（IPSSWM）阶段（P